# A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

> **NCT01278758** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** ASA404, DMXAA or DXAA

## Key facts

- **NCT ID:** NCT01278758
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278758, "A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01278758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*